Skip to main content
. Author manuscript; available in PMC: 2015 Mar 10.
Published in final edited form as: Am J Med Genet C Semin Med Genet. 2014 Mar 10;166(1):68–75. doi: 10.1002/ajmg.c.31385

Figure 1. Genotype results for the study population for several key pharmacogenomic genes being reported.

Figure 1

Rather than being reported in the GPS as shown, each patient’s specific result is translated into a corresponding traffic alert signal color (with a level of evidence designation) with accompanying decision-support information. For some genotypes like those in CYP2C19, this first requires assignment of each genotype into the corresponding enzymatic phenotype group (ultrarapid metabolizer, extensive metabolizer, intermediate metabolizer, poor metabolizer). Genotypes from CYP2C9 are incorporated into a warfarin dosing calculator, with each patient’s results delivered to the physician as a recommended starting dose. NA=genotype not called.